Archive · 2 Jun 2025
New COVID-19 Variant NB.1.8.1 Emerges Globally
A new COVID-19 variant, NB.1.8.1, is spreading in several countries.
It's a sub-variant of Omicron, and initial studies suggest it may spread more easily due to changes in the spike protein.
While symptoms are similar to previous Omicron strains, which include fatigue, fever, and sore throat, current evidence indicates it's not causing more severe illness.
Vaccines aimed at the JN.1 variant should still help.
Medical experts recommend boosters, particularly for those at risk.
However, existing vaccines are expected to provide protection.
NB.1.8.1, an Omicron subvariant, is spreading in multiple countries.
The variant has been detected in Asia, Australia, the US, and Europe.
Early lab tests show the variant spreads more easily.
Symptoms align with other Omicron variants, and WHO hasn't reported increased severity.
Vaccines targeting JN.1 are expected to offer some protection.
- Who
- World Health Organization, public, and medical experts.
- What
- Spread of new COVID-19 variant NB.1.8.1.
- When
- Detected in January 2025; cases rising recently.
- Where
- Asia, Australia, and the US
- Why
- New variant detected with mutations.
Severity Concerns
Vaccine Effectiveness
Disease Impact
Severity Concerns
Those with health issues are still at risk.
Vaccine Effectiveness
Current vaccines, especially boosters, are likely to prevent severe illness.
- Variant Name
- NB.1.8.1
- Variant Type
- Omicron subvariant
- Affected Regions
- Asia, Australia, US
- Common Symptoms
- Fatigue, fever, cough
- Vaccine Effectiveness
- Vaccines offer protection
